{"id":3115,"date":"2018-08-29T15:38:12","date_gmt":"2018-08-29T10:08:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3115"},"modified":"2021-07-24T12:57:03","modified_gmt":"2021-07-24T07:27:03","slug":"snippet-5","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-5","title":{"rendered":"Snippet"},"content":{"rendered":"

National health authorities, U.K.’s NICE determines Gilead’s cancer<\/a> cell therapy exorbitant<\/strong><\/h3>\n

The National Institute for Health and Care Excellence (NICE) found Gilead’s cancer cell therapy, Yescarta\u00a0to be clinically efficacious for treating a type of lymphoma, but no ample evidence is present to estimate the benefit over salvage chemotherapy. NICE took a considerable view on Yescarta’s\u00a0efficaciousness, considering the cell therapy that delivered good response rates, overall survival and progression-free survival in treating diffuse large B-cell lymphoma. Therapies cost surpassed USD 65,000 per quality-adjusted life years. In the U.S., Yescarta carries a list price of USD 373,000. A government in England cost agency judged the cancer cell therapy as exorbitant that cannot be included for coverage through the state-funded health system. This obstructs the plans of biotech to get the CAR-T treatment available in the country.\u00a0It was followed by the permission of Yescarta’s use from the European Commission\u00a0across EU countries.\u00a0 This leads to determine NICE if covering a new therapy is a cost-effective use of National Health Service resources or not.<\/p>\n","protected":false},"excerpt":{"rendered":"

National health authorities, U.K.’s NICE determines Gilead’s cancer cell therapy exorbitant The National Institute for Health and Care Excellence (NICE) found Gilead’s cancer cell therapy, Yescarta\u00a0to be clinically efficacious for treating a type of lymphoma, but no ample evidence is present to estimate the benefit over salvage chemotherapy. NICE took a considerable view on Yescarta’s\u00a0efficaciousness, […]<\/p>\n","protected":false},"author":1,"featured_media":3097,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[810,258,794,739,16932],"industry":[17225],"therapeutic_areas":[17235],"class_list":["post-3115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-car-t","tag-gene-therapy","tag-gilead","tag-snippet","tag-yescarta","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy"],"acf":[],"yoast_head":"\nSnippet - Yescarta - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"The National Institute for Health and Care Excellence (NICE) found Gilead's cancer cell therapy, Yescarta\u00a0to be clinically efficacious for ......\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-5\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet - Yescarta - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"The National Institute for Health and Care Excellence (NICE) found Gilead's cancer cell therapy, Yescarta\u00a0to be clinically efficacious for ......\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-5\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-29T10:08:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet - Yescarta - DelveInsight Business Research LLP","description":"The National Institute for Health and Care Excellence (NICE) found Gilead's cancer cell therapy, Yescarta\u00a0to be clinically efficacious for ......","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-5","og_locale":"en_US","og_type":"article","og_title":"Snippet - Yescarta - DelveInsight Business Research LLP","og_description":"The National Institute for Health and Care Excellence (NICE) found Gilead's cancer cell therapy, Yescarta\u00a0to be clinically efficacious for ......","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-5","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-08-29T10:08:12+00:00","article_modified_time":"2021-07-24T07:27:03+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-5","url":"https:\/\/www.delveinsight.com\/blog\/snippet-5","name":"Snippet - Yescarta - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-5#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-5#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","datePublished":"2018-08-29T10:08:12+00:00","dateModified":"2021-07-24T07:27:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The National Institute for Health and Care Excellence (NICE) found Gilead's cancer cell therapy, Yescarta\u00a0to be clinically efficacious for ......","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-5"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-5#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer.jpg","width":640,"height":400,"caption":"Cancer"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021352\/cancer-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippet<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Yescarta<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Snippet<\/span>","<span class=\"advgb-post-tax-term\">Yescarta<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 29, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 29, 2018 3:38 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3115"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3115\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3097"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3115"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3115"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}